相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
Bin Du et al.
CANCER LETTERS (2020)
The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right
Derek S. Park et al.
CANCER RESEARCH (2019)
SIAN: software for structural identifiability analysis of ODE models
Hoon Hong et al.
BIOINFORMATICS (2019)
Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions
Evgeni V. Nikolaev et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment
James M. Greene et al.
JCO CLINICAL CANCER INFORMATICS (2019)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
Engineered promoters enable constant gene expression at any copy number in bacteria
Thomas H. Segall-Shapiro et al.
NATURE BIOTECHNOLOGY (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Type I interferons as Regulators of Lung inflammation
Spyridon Makris et al.
FRONTIERS IN IMMUNOLOGY (2017)
A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination
Eduardo D. Sontag
CELL SYSTEMS (2017)
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy
Joseph Ciccolini et al.
CANCER RESEARCH (2017)
Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy
Heinz Schaettler et al.
JOURNAL OF MATHEMATICAL BIOLOGY (2016)
Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
Junjie Wu et al.
BMC CANCER (2016)
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Martina Ahlmann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
LIMITING THE DEVELOPMENT OF ANTI-CANCER DRUG RESISTANCE IN A SPATIAL MODEL OF MICROMETASTASES
Ami B. Shah et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2016)
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva et al.
CANCER LETTERS (2015)
Fundamental limitation of the instantaneous approximation in fold-change detection models
Maja Skataric et al.
IET SYSTEMS BIOLOGY (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Combinatorial strategies for the induction of immunogenic cell death
Lucillia Bezu et al.
FRONTIERS IN IMMUNOLOGY (2015)
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory
Junjie Wu et al.
ONCOIMMUNOLOGY (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
DYNAMICS AND CONTROL OF A MATHEMATICAL MODEL FOR METRONOMIC CHEMOTHERAPY
Urszula Ledzewicz et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2015)
Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model
Junjie Wu et al.
CANCER LETTERS (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
Chong-Sheng Chen et al.
NEOPLASIA (2014)
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy
Luis Sanchez-Perez et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Regulation of type I interferon responses
Lionel B. Ivashkiv et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Immune-suppressive properties of the tumor microenvironment
Juergen C. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Chemoimmunotherapy: reengineering tumor immunity
Gang Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Utility of Paradoxical Components in Biological Circuits
Yuval Hart et al.
MOLECULAR CELL (2013)
Mechanisms and insights into drug resistance in cancer
Hiba Zahreddine et al.
FRONTIERS IN PHARMACOLOGY (2013)
HMGB1: the central cytokine for all lymphoid cells
Guanqiao Li et al.
FRONTIERS IN IMMUNOLOGY (2013)
VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression
Joshua C. Doloff et al.
CANCER RESEARCH (2012)
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
Nicolas Penel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Joannes F. M. Jacobs et al.
LANCET ONCOLOGY (2012)
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model
Yifeng Xia et al.
NATURE CELL BIOLOGY (2012)
CD73: a potent suppressor of antitumor immune responses
Paul. A. Beavis et al.
TRENDS IN IMMUNOLOGY (2012)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Raquel De Souza et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Surface-exposed calreticulin in the interaction between dying cells and phagocytes
Isabelle Martins et al.
CLEARANCE OF DYING CELLS IN HEALTHY AND DISEASED IMMUNE SYSTEMS (2010)
Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment
Thais Helena Gasparoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Alberto Mantovani et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Fold-change detection and scalar symmetry of sensory input fields
Oren Shoval et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Immunogenic cell death modalities and their impact on cancer treatment
Oliver Kepp et al.
APOPTOSIS (2009)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
Daniele Generali et al.
CLINICAL CANCER RESEARCH (2009)
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Hideyuki Yanai et al.
NATURE (2009)
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Michael R. Elliott et al.
NATURE (2009)
Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer
Junko Yokokawa et al.
CLINICAL CANCER RESEARCH (2008)
Macrophage polarization in tumour progression
Antonio Sica et al.
SEMINARS IN CANCER BIOLOGY (2008)
Role of myeloid cells in tumor angiogenesis and growth
Farbod Shojaei et al.
TRENDS IN CELL BIOLOGY (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
Urban Emmenegger et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?
Robert J. Gillies et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The incoherent feed-forward loop accelerates the response-time of the gal system of Escherichia coli
S Mangan et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations
LG de Pillis et al.
JOURNAL OF THEORETICAL BIOLOGY (2006)
A validated mathematical model of cell-mediated immune response to tumor growth
LG de Pillis et al.
CANCER RESEARCH (2005)
Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor
I Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition
MH Lind et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Structure and function of the feed-forward loop network motif
S Mangan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Role of tumor-associated gangliosides in cancer progression
S Birklé et al.
BIOCHIMIE (2003)
The tumor microenvironment: a critical determinant of neoplastic evolution
LCLT van Kempen et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
The macrophage growth factor CSF-1 in mammary gland development and tumor progression
EY Lin et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2002)
分享论文
